Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camptothecin - BlueLink Pharmaceuticals/Calando Pharmaceuticals

Drug Profile

Camptothecin - BlueLink Pharmaceuticals/Calando Pharmaceuticals

Alternative Names: Camptothecin-nanoparticle-cerulean; CRLX 101; Cyclosert-CPT; Cyclosert™-enhanced camptothecin; IT-101; NLG 207

Latest Information Update: 21 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insert Therapeutics
  • Developer AstraZeneca; BlueLink Pharmaceuticals; Cerulean Pharma; Insert Therapeutics; Massachusetts General Hospital; National Cancer Institute (USA); University of North Carolina
  • Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Preclinical Breast cancer
  • No development reported Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 20 Nov 2018 Phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Late-stage disease, Hormone refractory, Second-line therapy or greater) in USA (IV) (NCT03531827)
  • 01 Nov 2018 Cerulean Pharma completes a phase Ib trial for Ovarian cancer, fallopian tube or peritoneal cancer (Combination therapy, Recurrent) in USA (IV)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top